Literature DB >> 27104278

Correlation between stage shift and differences in mortality in the European Randomised study of Screening for Prostate Cancer (ERSPC).

Leonard P Bokhorst1, Marco Zappa2, Sigrid V Carlsson3,4, Maciej Kwiatkowski5, Louis Denis6, Alvaro Paez7, Jonas Hugosson8, Sue Moss9, Anssi Auvinen10, Monique J Roobol11.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27104278      PMCID： PMC5072450          DOI： 10.1111/bju.13505

Source DB:  PubMed          Journal:  BJU Int        ISSN： 1464-4096            Impact factor:   5.588


× No keyword cloud information.
  9 in total

1.  Perspective: Enforce the clinical guidelines.

Authors:  Monique Roobol
Journal:  Nature       Date:  2015-12-17       Impact factor: 49.962

2.  Screening for prostate cancer--the controversy that refuses to die.

Authors:  Michael J Barry
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

Review 3.  Advanced breast cancer and breast cancer mortality in randomized controlled trials on mammography screening.

Authors:  Philippe Autier; Clarisse Héry; Jari Haukka; Mathieu Boniol; Graham Byrnes
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

4.  Differences in Treatment and Outcome After Treatment with Curative Intent in the Screening and Control Arms of the ERSPC Rotterdam.

Authors:  Leonard P Bokhorst; Ries Kranse; Lionne D F Venderbos; Jolanda W Salman; Geert J L H van Leenders; Fritz H Schröder; Chris H Bangma; Monique J Roobol
Journal:  Eur Urol       Date:  2014-10-18       Impact factor: 20.096

5.  Do Treatment Differences between Arms Affect the Main Outcome of ERSPC Rotterdam?

Authors:  Leonard P Bokhorst; Lionne D F Venderbos; Fritz H Schröder; Chris H Bangma; Ewout W Steyerberg; Monique J Roobol
Journal:  J Urol       Date:  2015-02-16       Impact factor: 7.450

6.  Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer.

Authors:  Carlotta Buzzoni; Anssi Auvinen; Monique J Roobol; Sigrid Carlsson; Sue M Moss; Donella Puliti; Harry J de Koning; Chris H Bangma; Louis J Denis; Maciej Kwiatkowski; Marcos Lujan; Vera Nelen; Alvaro Paez; Marco Randazzo; Xavier Rebillard; Teuvo L J Tammela; Arnauld Villers; Jonas Hugosson; Fritz H Schröder; Marco Zappa
Journal:  Eur Urol       Date:  2015-03-16       Impact factor: 20.096

Review 7.  Risk stratification in prostate cancer screening.

Authors:  Monique J Roobol; Sigrid V Carlsson
Journal:  Nat Rev Urol       Date:  2012-12-18       Impact factor: 14.432

8.  The effect of study arm on prostate cancer treatment in the large screening trial ERSPC.

Authors:  Tineke Wolters; Monique J Roobol; Ewout W Steyerberg; Roderick C N van den Bergh; Chris H Bangma; Jonas Hugosson; Stefano Ciatto; Maciej Kwiatkowski; Arnauld Villers; Marcos Luján; Vera Nelen; Teuvo L J Tammela; Fritz H Schröder
Journal:  Int J Cancer       Date:  2010-05-15       Impact factor: 7.396

9.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Marco Zappa; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Liisa Määttänen; Hans Lilja; Louis J Denis; Franz Recker; Alvaro Paez; Chris H Bangma; Sigrid Carlsson; Donella Puliti; Arnauld Villers; Xavier Rebillard; Matti Hakama; Ulf-Hakan Stenman; Paula Kujala; Kimmo Taari; Gunnar Aus; Andreas Huber; Theo H van der Kwast; Ron H N van Schaik; Harry J de Koning; Sue M Moss; Anssi Auvinen
Journal:  Lancet       Date:  2014-08-06       Impact factor: 79.321
  9 in total
  4 in total

Review 1.  What's new in screening in 2015?

Authors:  Sigrid V Carlsson; Monique J Roobol
Journal:  Curr Opin Urol       Date:  2016-09       Impact factor: 2.309

2.  Novel PSCA targeting scFv-fusion proteins for diagnosis and immunotherapy of prostate cancer.

Authors:  Claudia Kessler; Alessa Pardo; Mehmet K Tur; Stefan Gattenlöhner; Rainer Fischer; Katharina Kolberg; Stefan Barth
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-30       Impact factor: 4.322

3.  Treatment patterns of high-dose-rate and low-dose-rate brachytherapy as monotherapy for prostate cancer.

Authors:  Justin Barnes; William R Kennedy; Benjamin W Fischer-Valuck; Brian C Baumann; Jeff M Michalski; Hiram A Gay
Journal:  J Contemp Brachytherapy       Date:  2019-08-29

4.  LncRNA CCAT1 promotes prostate cancer cells proliferation, migration, and invasion through regulation of miR-490-3p/FRAT1 axis.

Authors:  Xiaowei Cai; Yiheng Dai; Peng Gao; Guanyu Ren; Dingcai Cheng; Bo Wang; Yi Wang; Jiang Yu; Yiheng Du; Xizhi Wang; Boxin Xue
Journal:  Aging (Albany NY)       Date:  2021-07-28       Impact factor: 5.682
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.